

Quris – Biomed 2022

Questions for categories: **Biotech/Pharma**

- **Investment Rational**

Quris is a disruptive AI-pharma company that is the leader in AI-based drug safety prediction, addressing pharma's biggest, multi-billion-dollar problem. Strategic collaborations with Merck, a top-20 pharma company; and NYSCF, world leader in stem-cell technology. First AI-based drug preparing for clinical testing this year. Led by Nobel laureate, by Moderna co-founder, and a stellar team of renown technology pioneers.
- **Business Strategy**

Quris is using its Bio-AI prediction platform for 3 main business applications: (i) **Pharma Services**: improving candidate drugs selection to increase clinical trials' success rate; (ii) **Drug Pipeline**: Quris utilizes its prediction platform capacities to develop select promising drug candidates at an early stage; and (iii) **Personalized Drug Safety**: Quris to apply its prediction technology and stem-cell database to personalize drug safety.
- **Core Technology**

Quris' clinical prediction platform combines three unique elements: (i) **'Patient-on-a-Chip'** – testing candidate drugs on 'miniaturized patients' that are comprised from 'miniature organs'; (ii) **Artificial intelligence** – Unique BIO-AI approach; 18 patents granted or pending; and (iii) **Stem-cell genomic diversity** – testing genomically diverse stem-cell database; partnering with New York Stem Cell Foundation (NYSCF) – a world leader in stem-cell automation.
- **Product Profile/Pipeline**

Quris to enter umbrella agreements with two leading research institutes in the US and Israel for priority access to promising drug candidates. Advanced discussions with a leading pharmaceutical company to enter a multi-million prediction service agreement. Developing a novel formula for Fragile-X Syndrome in collaboration with the Hebrew University with promising early results.
- **What's Next?**

Quris's AI-based Fragile-X drug preparing for clinical testing later this year. Advanced discussion and diligence with leading PE's and funds regarding additional funding. Expect to finalize the training of Quris' AI prediction platform by screening more than a thousand drugs with known level of toxicity within 12 months.